The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Schmitt, Kyle C ^a   Reith, Maarten E A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZATROPINE; BETA CFT; COCAINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; MODAFINIL; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; VANOXERINE; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; DOPAMINE UPTAKE INHIBITOR;

ARTICLE; BINDING AFFINITY; COCAINE DEPENDENCE; COMPUTER MODEL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; MOLECULAR DOCKING; MUTATIONAL ANALYSIS; STRUCTURE ACTIVITY RELATION; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION;

BENZHYDRYL COMPOUNDS; CELL LINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HUMANS; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 80054728808     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025790     Document Type: Article

References (91)

1. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ, (2004) Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 55: 1031-1040.
2. Marchant N, Kamel F, Echlin K, Grice J, Lewis M, et al. (2009) Modafinil improves rapid shifts of attention. Psychopharmacology 202: 487-495.
3. Tsanov M, Lyons DG, Barlow S, González Reyes RE, O'Mara SM, (2010) The psychostimulant modafinil facilitates water maze performance and augments synaptic potentiation in dentate gyrus. Neuropharmacology 59: 9-19.
4. Regenthal R, Koch H, Köhler C, Preiss R, Krügel U, (2009) Depression-like deficits in rats improved by subchronic modafinil. Psychopharmacology 204: 627-639.
5. Ninan PT, Hassman HA, Glass SJ, McManus FC, (2004) Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clinical Psychiatry 65: 414-420.
6. Lam JY, Freeman MK, Cates ME, (2007) Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Annals of Pharmacotherapy 41: 1005-1012.
7. Whiting E, Chenery HJ, Chalk J, Darnell R, Copland DA, (2008) The explicit learning of new names for known objects is improved by dexamphetamine. Brain Lang 104: 254-261.
8. Xu T-X, Ma Q, Spealman RD, Yao W-D, (2010) Amphetamine modulation of long-term potentiation in the prefrontal cortex: dose dependency, monoaminergic contributions, and paradoxical rescue in hyperdopaminergic mutant. J Neurochem 115: 1643-1654.
9. Zeeuws I, Deroost N, Soetens E, (2010) Effect of an acute d-amphetamine administration on context information memory in healthy volunteers: evidence from a source memory task. Hum Psychopharmacol 25: 326-334.
10. Rasetti R, Mattay VS, Stankevich B, Skjei K, Blasi G, et al. (2010) Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacology 35: 2101-2109.
11. Minzenberg MJ, Carter CS, (2008) Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33: 1477-1502.
12. Tsuang MT, Lyons MJ, Harley RM, Xian H, Eisen S, et al. (1999) Genetic and environmental influences on transitions in drug use. Behav Genet 29: 473-479.
13. Ridenour TA, Maldonado-Molina M, Compton WM, Spitznagel EL, Cottler LB, (2005) Factors associated with the transition from abuse to dependence among substance abusers: implications for a measure of addictive liability. Drug and Alcohol Dependence 80: 1-14.
14. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, (2005) A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205-211.
15. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW, (2008) Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33: 761-768.
16. Vosburg SK, Hart CL, Haney M, Rubin E, Foltin RW, (2010) Modafinil does not serve as a reinforcer in cocaine abusers. Drug and Alcohol Dependence 106: 233-236.
17. Ballon JS, Feifel D, (2006) A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clinical Psychiatry 67: 554-566.
18. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, et al. (2009) Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.
19. Rothman RB, Baumann MH, Prisinzano TE, Newman AH, (2008) Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol 75: 2-16.
20. Li S-M, Kopajtic TA, O'Callaghan MJ, Agoston GE, Cao J, et al. (2011) N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects. J Pharmacol Exp Ther 336: 575-585.
21. Loland CJ, Desai RI, Zou M-F, Cao J, Grundt P, et al. (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Molecular Pharmacology 73: 813-823.
22. Woolverton WL, Wang Z, (2004) Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 486: 251-257.
23. Wee S, Carroll FI, Woolverton WL, (2006) A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology 31: 351-362.
24. Kimmel HL, Negus SS, Wilcox KM, Ewing SB, Stehouwer J, et al. (2008) Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav 90: 453-462.
25. Czoty PW, Martelle JL, Carroll FI, Nader MA, (2010) Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates. Pharmacol Biochem Behav 96: 274-278.
26. Newman JL, Negus SS, Lozama A, Prisinzano TE, Mello NK, (2010) Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Experimental Clin Psychopharmacol 18: 395-408.
27. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E, (2005) Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature 437: 215-223.
28. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, et al. (2007) LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317: 1390-1393.
29. Singh SK, Piscitelli CL, Yamashita A, Gouaux E, (2008) A competitive inhibitor traps LeuT in an open-to-out conformation. Science 322: 1655-1661.
30. Huang X, Zhan C-G, (2007) How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophysical Journal 93: 3627-3639.
31. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, et al. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11: 780-789.
32. Shi L, Quick M, Zhao Y, Weinstein H, Javitch JA, (2008) The mechanism of a neurotransmitter:sodium symporter-inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell 30: 667-677.
33. Piscitelli CL, Krishnamurthy H, Gouaux E, (2010) Neurotransmitter/sodium symporter orthologue LeuT has a single high-affinity substrate site. Nature 468: 1129-1132.
34. Claxton DP, Quick M, Shi L, de Carvalho FD, Weinstein H, et al. (2010) Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters. Nat Struct Mol Biol 17: 822-829.
35. Zhao Y, Terry D, Shi L, Weinstein H, Blanchard SC, et al. (2010) Single-molecule dynamics of gating in a neurotransmitter transporter homologue. Nature 465: 188-193.
36. Kniazeff J, Shi L, Loland CJ, Javitch JA, Weinstein H, et al. (2008) An intracellular interaction network regulates conformational transitions in the dopamine transporter. J Biol Chem 283: 17691-17701.
37. Quick M, Winther A-ML, Shi L, Nissen P, Weinstein H, et al. (2009) Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation. Proc Natl Acad Sci 106: 5563-5568.
38. Singh SK, Yamashita A, Gouaux E, (2007) Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448: 952-956.
39. Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith MEA, et al. (2009) Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol 16: 652-657.
40. Reith ME, Berfield JL, Wang LC, Ferrer JV, Javitch JA, (2001) The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 276: 29012-29018.
41. Loland CJ, Norregaard L, Litman T, Gether U, (2002) Generation of an activating Zn(2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc Natl Acad Sci 99: 1683-1688.
42. Schmitt KC, Zhen J, Kharkar P, Mishra M, Chen N, et al. (2008) Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. J Neurochem 107: 928-940.
43. Chen N, Vaughan RA, Reith ME, (2001) The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J Neurochem 77: 1116-1127.
44. Chen N, Zhen J, Reith MEA, (2004) Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine. J Neurochem 89: 853-864.
45. Loland CJ, Norregaard L, Gether U, (1999) Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site. J Biol Chem 274: 36928-36934.
46. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
47. Schmitt KC, Mamidyala S, Biswas S, Dutta AK, Reith MEA, (2010) Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter. J Neurochem 112: 1605-1618.
48. Beuming T, Shi L, Javitch JA, Weinstein H, (2006) A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Molecular Pharmacology 70: 1630-1642.
49. Forrest LR, Tavoulari S, Zhang Y-W, Rudnick G, Honig B, (2007) Identification of a chloride ion binding site in Na+/Cl--dependent transporters. Proc Natl Acad Sci 104: 12761-12766.
50. Zomot E, Bendahan A, Quick M, Zhao Y, Javitch JA, et al. (2007) Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature 449: 726-730.
51. Labute P, (2008) The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29: 1693-1698.
52. Laskowski R, MacArthur M, Moss D, Thornton J, (1993) PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography 26: 283-291.
53. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, et al. (2006) Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319: 561-569.
54. Zhao Y, Terry DS, Shi L, Quick M, Weinstein H, et al. (2011) Substrate-modulated gating dynamics in a Na+-coupled neurotransmitter transporter homologue. Nature 474: 109-113.
55. Quick M, Yano H, Goldberg NR, Duan L, Beuming T, et al. (2006) State-dependent conformations of the translocation pathway in the tyrosine transporter Tyt1, a novel neurotransmitter:sodium symporter from Fusobacterium nucleatum. J Biol Chem 281: 26444-26454.
56. Chen N, Rickey J, Reith MEA, (2003) Na+ stimulates binding of dopamine to the dopamine transporter in cells but not in cell-free preparations. J Neurochem 86: 678-686.
57. Chen N, Rickey J, Berfield JL, Reith MEA, (2004) Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding. J Biol Chem 279: 5508-5519.
58. Liang Y, Zhen J, Chen N, Reith M, (2009) Interaction of catechol and non-catechol substrates with externally or internally facing dopamine transporters. J Neurochem 109: 981-994.
59. Hong WC, Amara SG, (2010) Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J Biol Chem 285: 32616-32626.
60. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, et al. (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Molecular Pharmacology 66: 675-682.
61. Glennon RA, Young R, Martin BR, Dal Cason TA, (1995) Methcathione ("cat"): an enantiomeric potency comparison. Pharmacol Biochem Behav 50: 601-606.
62. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, et al. (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307: 138-145.
63. Eckerman DA, Moy SS, Perkins AN, Patrick KS, Breese GR, (1991) Enantioselective behavioral effects of threo-methylphenidate in rats. Pharmacol Biochem Behav 40: 875-880.
64. Williard RL, Middaugh LD, Zhu H-JB, Patrick KS, (2007) Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behavioural Pharmacology 18: 39-51.
65. Cao J, Prisinzano TE, Okunola OM, Kopajtic T, Shook M, et al. (2010) Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues. ACS Med Chem Lett 2: 48-52.
66. Donovan JL, Malcolm RJ, Markowitz JS, DeVane CL, (2003) Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies. Ther Drug Monitor 25: 197-202.
67. Huang X, Gu HH, Zhan C-G, (2009) Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J Phys Chem B 113: 15057-15066.
68. Hill ER, Huang X, Zhan C-G, Ivy Carroll F, Gu HH, (2011) Interaction of tyrosine 151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113. Neuropharmacology 61: 112-120.
69. Gedeon P, Indarte M, Surratt C, Madura J, (2010) Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer. Proteins 78: 797-811.
70. Shan J, Javitch JA, Shi L, Weinstein H, (2011) The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. PLoS ONE 6: e16350 doi:10.1371/journal.pone.0016350.
71. Mignot E, Nishino S, Guilleminault C, Dement WC, (1994) Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17: 436-437.
72. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301: 1148-1154.
73. Tahsili-Fahadan P, Carr GV, Harris GC, Aston-Jones G, (2010) Modafinil blocks reinstatement of extinguished opiate-seeking in rats: mediation by a glutamate mechanism. Neuropsychopharmacology 35: 2203-2210.
74. Deroche-Gamonet V, Darnaudéry M, Bruins-Slot L, Piat F, Le Moal M, et al. (2002) Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology 161: 387-395.
75. Gold LH, Balster RL, (1996) Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 126: 286-292.
76. Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, et al. (2010) Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 95: 449-456.
77. Wuo-Silva R, Fukushiro DF, Borçoi AR, Fernandes HA, Procópio-Souza R, et al. (2011) Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study. Addict Biol doi:10.1111/j.1369-1600.2011.00341.x.
78. Jasinski DR, (2000) An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 14: 53-60.
79. Søgaard U, Michalow J, Butler B, Lund Laursen A, Ingersen SH, et al. (1990) A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. Int Clinical Psychopharmacol 5: 237-251.
80. Kopajtic TA, Liu Y, Surratt CK, Donovan DM, Newman AH, et al. (2010) Dopamine transporter-dependent and-independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability. J Pharmacol Exp Ther 335: 703-714.
81. Tella SR, Ladenheim B, Cadet JL, (1997) Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther 281: 508-513.
82. Velázquez-Sánchez C, Ferragud A, Hernández-Rabaza V, Nácher A, Merino V, et al. (2009) The dopamine uptake inhibitor 3 alpha-[bis(4′-fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward. Neuropsychopharmacology 34: 2497-2507.
83. Hiranita T, Soto PL, Newman AH, Katz JL, (2009) Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther 329: 677-686.
84. Tanda G, Newman AH, Ebbs AL, Tronci V, Green JL, et al. (2009) Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther 330: 802-809.
85. Batman AM, Dutta AK, Reith MEA, Beardsley PM, (2010) The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization. Eur J Pharmacol 648: 127-132.
86. Campbell VC, Kopajtic TA, Newman AH, Katz JL, (2005) Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs. J Pharmacol Exp Ther 315: 631-640.
87. Li S-M, Newman AH, Katz JL, (2005) Place conditioning and locomotor effects of N-substituted, 4′,4''-difluorobenztropine analogs in rats. J Pharmacol Exp Ther 313: 1223-1230.
88. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL, (2005) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25: 1889-1893.
89. Desai RI, Kopajtic TA, French D, Newman AH, Katz JL, (2005) Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs. J Pharmacol Exp Ther 315: 397-404.
90. Volz TJ, Kim M, Schenk JO, (2004) Covalent and noncovalent chemical modifications of arginine residues decrease dopamine transporter activity. Synapse 52: 272-282.
91. Herin DV, Rush CR, Grabowski J, (2010) Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann NY Acad Sci 1187: 76-100.